Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen other Revenues (Royalties, Milestone & Collaboration Revenues) — Worldwide ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Income & Note 2 (XBRL)
Latest, Q2 2026
517
Period ended Jun 30, 2026
Change on a year earlier
+26.7%
408 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
36
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Revenues (Royalties, Milestone & Collaboration Revenues) — Worldwide ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 517 | +26.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 400 | +44.9% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 499 | +34.9% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 420 | +19.3% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 408 | +17.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 276 | -16.1% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 370 | +1.9% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 352 | -0.8% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 347 | +14.5% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 329 | +27.0% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 363 | +26.5% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 355 | -14.5% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 303 | -3.2% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 259 | -48.9% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 287 | -50.1% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 415 | +7.5% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2022 | Jun 30, 2022 | 313 | -24.0% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 507 | +64.1% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 575 | +91.7% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2021 | Sep 30, 2021 | 386 | +21.0% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 412 | +38.3% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 309 | +15.7% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 300 | -5.1% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 319 | +16.4% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 298 | +0.3% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 267 | -1.5% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2019 | Dec 31, 2019 | 316 | +38.0% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2019 | Sep 30, 2019 | 274 | -30.5% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2019 | Jun 30, 2019 | 297 | -21.8% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2019 | Mar 31, 2019 | 271 | +28.4% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 229 | -1.7% | Form 10-K (filed 2021-02-09) ↗ |
| Q3 2018 | Sep 30, 2018 | 394 | +23.1% | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2018 | Jun 30, 2018 | 380 | +61.0% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2018 | Mar 31, 2018 | 211 | -20.4% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 233 | -22.8% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 320 | +8.5% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jun 30, 2017 | 236 | +10.3% | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2017 | Mar 31, 2017 | 265 | -8.0% | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2016 | Dec 31, 2016 | 302 | +45.9% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2016 | Sep 30, 2016 | 295 | +42.5% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 214 | +47.6% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 288 | +81.1% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 207 | – | Form 10-K (filed 2018-02-13) ↗ |
| Q3 2015 | Sep 30, 2015 | 207 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 145 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 159 | – | 10-Q FY2015 (XBRL) ↗ |
Breakdown
What makes up other revenues (royalties, milestone & collaboration revenues) — worldwide ($m)
Cite this data
StockData. (2026). Amgen Other Revenues (Royalties, Milestone & Collaboration Revenues) — Worldwide ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/rev_other_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.